Tianshu Pharmaceutical, Subsidiary of Nanjing Vcare, Selected to Build "Hubei Provincial High-End API and Pharmaceutical Intermediates CDMO R&D and Pilot-Scale Production Platform"

2025-07-02

　　Recently, the Hubei Provincial Department of Economy and Information Technology announced the 2025 provincial-level manufacturing pilot-scale platform cultivation and construction list. The Hubei Provincial High-End APIand Pharmaceutical Intermediates CDMOR&D and Pilot-Scale Production Platform, undertaken by Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), a subsidiary of Nanjing Vcare Pharmatech Co., Ltd. (Nanjing Vcare), was successfully included in this list.

　　"Pilot-scale testing" refers to the transitional experimentation that moves a new product from the trial development stage into the production process. Manufacturing pilot-scale testing is a crucial step in advancing the industrialization of scientific research achievements. It serves as a vital method for promoting technological iteration, process improvement, and product innovation. Its core purpose is to accelerate the transformation of innovative results into tangible productive forces.

　　The High-End API and Pharmaceutical Intermediates CDMO R&D and Pilot-Scale Production Platform being constructed by Tianshu Pharmaceutical is centered around the company's overarching product development concept of "Integrated R&D Innovation, Pilot-Scale Incubation and Acceleration, and Industrial Empowerment and Enhancement." It streamlines the critical intermediary steps in the CDMO project process for APIs and pharmaceutical intermediates, from R&D to industrial-scale supply services. This initiative establishes a comprehensive service system encompassing product R&D, pilot-scale testing, and industrial production, enabling Tianshu Pharma to consistently provide high-quality, full-industry-chain CRO/CDMO services to domestic and international clients.

Prev

Tianshu Pharmaceutical, Subsidiary of Nanjing Vcare, Designated as "2025 Hubei SME Technology Center"

Next

Nanjing Vcare Ranked Top 8 in "China's Top 20 Pharmaceutical CRO Enterprises" for Four Consecutive Years